Eikon Therapeutics priced an upsized IPO that will raise roughly $381 million to advance its cancer pipeline, marking one of the largest biotech listings of the week. Across the same window, Agomab Therapeutics and SpyGlass Pharma raised a combined $350 million in separate Nasdaq offerings, signaling renewed public market appetite for drug developers. The flurry of offerings — which also included Veradermics and others — signals a tentative comeback for biotech IPOs after a multi‑year slowdown. Companies selling platform technologies and clinical assets are leveraging the window to fund mid‑stage programs and scale R&D operations.